Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. Tiacci E, De Carolis L, Simonetti E, Capponi M, et al. N Engl J Med 2021;384:1810-1823.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tiacci E, De Carolis L, Simonetti E, Capponi M, et al. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. N Engl J Med 2021;384:1810-1823.
PMID: 33979489